Spero's Scientific Exchange

Posters and Publications

Filter all Posters & Publications

Download a complete bibliography from each of our ongoing investigational programs below.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Resource Type
Year
Congress
Study Type
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
SPR720
Tebipenem HBr
SPR206

Tebipenem HBR

Microbiology
Clinical

Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial

2024
ARCHIVE
View Full Text Link
Open Resource

SPR720

Reviews

Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection

2024
ARCHIVE
View Full Text Link
Open Resource

Molecular Diagnostics

Serum Cell-free DNA-based Detection of Mycobacterium Avium Complex Infection

2024
ARCHIVE
View Full Text Link
Open Resource

SPR206

No items found.

Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment

2023
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720

2023
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections

2023
ARCHIVE
View Full Text Link
Open Resource

SPR206

No items found.

Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects

2023
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions

2023
ECCMID
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions

2023
ECCMID
ARCHIVE
View Full Text Link
Open Resource

HEOR

The Economic Burden of Adverse Events Requiring Acute Care Service from Outpatient Parenteral Antibiotic Treatment (OPAT)

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Effectiveness of TBP PI HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT PO

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

HEOR

Enterobacterales Resistance Patterns for Extended Spectrum β lactamase (ESBL) Positive and Multidrug Resistant (MDR) Urine Isolates Collected and Tested from 295 Outpatient US Facilities in 2019

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR206

Clinical
PK/PD

SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
Microbiology

Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide

2022
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

The 30-day economic burden of newly diagnosed complicated urinary tract infections in Medicare patients.

2022
ISPOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Sun Z, Su L, Cotroneo N, et al. Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections. Antimicrob Agents Chemother. 2022 May 2:e0239621

2022
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Lodise T, Nowak M, Rodriguez M. The 30-Day Economic Burden of Newly Diagnosed Complicated Urinary Tract Infections in Medicare Fee-for-Service Patients Who Resided in the Community. Antibiotics 2022; 11(5):578.

2022
HEOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Tebipenem pivoxil hydrobromide: Safety and tolerability profile of the first oral carbapenem for complicated urinary tract infection and acute pyelonephritis

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR
Microbiology

Relationship between receipt of prior antibiotics and presence of antibiotic resistance among adult outpatients with complicated urinary tract infection

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Efficacy of tebipenem pivoxil hydrobromide in patients with complicated urinary tract infection and associated bacteremia

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Activity of oral tebipenem against resistant Escherichia coli collected from urinary tract infections in Europe in 2020

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
PK/PD

Plasma pharmacokinetics and intrapulmonary penetration of tebipenem in healthy subjects

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
Microbiology

Effect of tebipenem on the normal gut microbiota of healthy adult population.

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

First performance study of ETEST TBP (Tebipenem) for Minimum Inhibitory Concentration (MIC) Determination for Enterobacterales

2022
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Patel G, Rodvold KA, Gupta VK, et al. Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment. Antimicrob Agents Chemother. 2022 Apr 14. doi: 10.1128/aac.02407-21. Epub ahead of print.

2022
PK/PD
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Gupta VK, Patel G, Gasink L, et al. Bioequivalence of Two Oral Formulations of Tebipenem Pivoxil Hydrobromide in Healthy Subjects. Clin Transl Sci. 2022 Apr 11. doi: 10.1111/cts.13280. Epub ahead of print.

2022
PK/PD
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Clinical stability indicators between ertapenem and tebipenem pivoxil, an oral carbapenem, in hospitalized adults with complicated urinary tract infection

2022
SHM
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Oral tebipenem pivoxil is non-inferior to IV ertapenem in complicated urinary tract infection and acute pyelonephritis: ADAPT-PO Study

2022
SHM
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Eckburg PB, Muir L, Critchley IA, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 2022;386:1327-38.

2022
Clinical
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016-2018. J Am Coll Emerg Physicians Open. 2022 Mar 17;3(2):e12694

2022
HEOR
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Aragaw WW, Cotroneo N, Stokes S, Pucci M, Critchley I, Gengenbacher M, Dick T. In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol Spectr. 2022 Jan 12;10(1):e0132121.

2022
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018. Open Forum Infect Dis. 2022 Jan 10;9(1):ofab591

2022
HEOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD

Population pharmacokinetic analyses for tebipenem after the administration of tebipenem pivoxil hydrobromide

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Healthcare resource utilization during hospitalizations with UTI in the US, 2018 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Medicare spending on urinary tract infections: a retrospective database analysis

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD
Non-Clinical

Pharmacokinetics-pharmacodynamics evaluation of tebipenem pivoxil hydrobromide using the 10-day hollow-fiber in vitro infection model 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
PK/PD

Effect of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics of tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy adult subjects 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
PK/PD

Bioequivalence of two oral formulations of tebipenem-pivoxil hydrobromide in healthy subjects. 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
PK/PD

Absorption, metabolism, and excretion of [14C]-tebipenem pivoxil hydrobromide (TBP-PI-HBr) following a single oral dose in healthy male subjects

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Development of tebipenem MIC antimicrobial susceptibility test for gram-negative bacteria on MicroScan dried gram-negative MIC panels

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem, an orally available carbapenem agent, against a collection of surveillance gram-positive clinical isolates

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with efflux, AmpC, and OprD mutations 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the US

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Descriptive epidemiology and outcomes of emergency department visits with cUTI in the US, 2016-2018 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical
Microbiology

Empiric antimicrobial prescribing for urinary tract infections in patients discharged from the emergency department

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Descriptive epidemiology of UTI hospitalizations in the US, 2018 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD
Non-Clinical
Microbiology

Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro infection model

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro analysis of AmpC β-lactamase induction by tebipenem in Enterobacterales and Pseudomonas aeruginosa

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource
No results found.
There are no results with this criteria. Try changing your search.

Unable to find what you were looking for?  

Download a complete bibliography from each of our ongoing investigational programs below.